Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE GE-Yokogawa Medical Systems Focuses on Cardiovascular Devices
February 5, 2001
-
ARCHIVE More Than 80% of Clinics Selected Fixed Sum Copayment: PJ Survey
February 5, 2001
-
ARCHIVE Boston Scientific Japan: New Balloon Catheters for PTCA
February 5, 2001
-
ARCHIVE 80.7% of Clinics Select Fixed Sum Copayment
February 5, 2001
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
February 5, 2001
-
ARCHIVE Takeda to Carry Out Reform with Global Standard: President Takeda
February 5, 2001
-
ARCHIVE 50% of Outpatients Should Pay Fixed Rate Copayment Overall: HIB
February 5, 2001
-
ARCHIVE WORLD NEWS IN BRIEF
February 5, 2001
-
ARCHIVE Korosho Holds 1st Explanatory Meeting for Prefectural Governmental Officials -2-
February 5, 2001
-
ARCHIVE JPA Holds National Convention to Prevent Dispensing Errors
February 5, 2001
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
February 5, 2001
-
ARCHIVE BUSINESS NEWS IN BRIEF
February 5, 2001
-
ARCHIVE Cost Curtailment Policy Should Now Target Hospitalization: JHEF Seminar
February 5, 2001
-
COMMENTARY -1-
February 5, 2001
-
ARCHIVE ON THE MOVE
February 5, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2001
-
COMMENTARY -2-
February 5, 2001
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
February 5, 2001
-
ARCHIVE Kirin Obtains Rights to Cerus's Allogeneic Cellular Immune Therapy Technology
February 5, 2001
-
ARCHIVE Takara Obtains Marketing Rights for Analysis Services from GeneFormatics
February 5, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…